The U.S. Supreme Court declined to hear CareDx's appeal in its false-advertising dispute with Natera, leaving intact lower-court rulings that denied CareDx damages over claims involving kidney transplant tests. The justices offered no explanation for their decision not to review whether CareDx was owed damages for allegedly misleading advertisements comparing Natera's Prospera test with CareDx's AlloSure test. In 2023, U.S. District Judge Colm Connolly overturned a nearly $45 million jury damages award after finding no evidence that Natera's statements actually misled customers, though he confirmed the jury's finding of false advertising. The 3rd U.S. Circuit Court of Appeals later affirmed that ruling. A Natera spokesperson said the firm was pleased with the outcome, while CareDx had argued that courts should presume deception when advertising is deliberately false.
CareDx IncSupreme Court refused to hear CareDx's appeal, upholding lower court rulings that denied damages in false-advertising dispute with Natera.
Natera IncSupreme Court rejected CareDx's appeal, leaving intact rulings favorable to Natera in false-advertising dispute.